Interleukin 28b Single Nucleotide Polymorphism (rs8099917) as a Predictive Factor of Response to Pegylated-IFN/Ribavirintherapy in Chronic HCV Patients

MOHAMED ALI SABER, M.D., WAHID DOSS, M.D.;; AHMED EL DEEB, M.Sc., MOHAMMAD EL-SAYED, M.D.;; ESMAT, M.D., GAMAL

doi:10.21608/mjcu.2021.203692

Interleukin 28b Single Nucleotide Polymorphism (rs8099917) as a Predictive Factor of Response to Pegylated-IFN/Ribavirintherapy in Chronic HCV Patients

Authors

The Departments of Endemic Medicine, Hepatogastroenterology, Faculty of Medicine, Cairo University*, Biochemistry & Molecular Biology Department, Theodor Bilharz Research Institute** and National Hepatology & Tropical Medicine Research Institute (NHTMRI)***

10.21608/mjcu.2021.203692

Abstract

Abstract Background: For Interleukin 28b Single nucleotide poly-morphism (SNP) rs8099917, the favourable T allele is asso-ciated with a higher SVR after PEG-IFN alpha/RBV therapy while the G allele is a risk factor for non-response. Aim of Study: To assess the value of Interleukin 28b (SNP) rs8099917 as a predictor of SVR. Patients and Methods: This study is a retrospective con-trolled study and was performed on a total number of 240 patients who were treated by PEG-IFN alpha/RBV for 48 weeks and (SNP) rs8099917 was done for the all patients. Results: TT genotype was more prevalent in SVR group than TG and GG genotypes. Conclusion: IL-28b single nucleotide polymorphism (SNP) rs8099917 is a strong pretreatment predictor of response to pegylated interferon and ribavirin therapy in egyptian patients chronically infected with HCV genotype 4.

Keywords